DelveInsight reports that over three key companies are actively developing more than three therapeutic candidates for Progressive Multifocal Leukoencephalopathy (PML).
Progressive Multifocal Leukoencephalopathy Overview:
Progressive multifocal leukoencephalopathy (PML) is a rare and often life-threatening brain infection. It can occur as a complication of certain medications for multiple sclerosis and other autoimmune disorders, or in individuals with HIV or specific blood and lymphatic cancers. The condition is caused by the John Cunningham (JC) virus, a polyomavirus that remains dormant in the kidneys and bone marrow of more than 60% of adults. PML develops when the virus is reactivated due to prolonged or drug-induced immune suppression, allowing it to invade the brain. This results in irreversible brain damage, severe cognitive and motor impairments, and a high risk of death. Currently, there are no approved therapies for treating PML.
Request for a detailed insights report on Progressive Multifocal Leukoencephalopathy pipeline insights
"Progressive Multifocal Leukoencephalopathy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Progressive Multifocal Leukoencephalopathy Therapeutics Market.
Key Takeaways from the Progressive Multifocal Leukoencephalopathy Pipeline Report
-
DelveInsight’s Progressive Multifocal Leukoencephalopathy (PML) pipeline report highlights an active landscape with over three companies developing more than three therapeutic candidates for PML.
-
Leading players such as Inhibikase Therapeutics, Neurimmune, Excision BioTherapeutics, I-MAB Biopharma, and others are advancing novel therapies to improve treatment options for PML.
-
Promising candidates in various stages of development include NT-I7, IkT-01427, and others.
-
In October 2022, Cellevolve Bio received FDA clearance for its IND application and Orphan Drug Designation for CE-VST01-JC, an allogeneic, off-the-shelf T cell therapy targeting the JC virus, which causes PML. The company plans to initiate ASCEND-JC, a Phase 2 placebo-controlled trial evaluating the therapy’s safety and efficacy, with first patient enrollment expected in the first half of 2023.
-
Earlier, in June 2020, the FDA granted Orphan Drug Designation to NT-I7, a long-acting human interleukin-7 (IL-7), for PML treatment. Subsequently, in February 2021, NeoImmuneTech received FDA clearance for an IND application to begin a pilot study assessing NT-I7’s safety and efficacy in PML patients.
Progressive Multifocal Leukoencephalopathy Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Progressive Multifocal Leukoencephalopathy Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Progressive Multifocal Leukoencephalopathy treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Progressive Multifocal Leukoencephalopathy market.
Download our free sample page report on Progressive Multifocal Leukoencephalopathy pipeline insights
Progressive Multifocal Leukoencephalopathy Emerging Drugs
-
NT-I7: NeoImmuneTech
-
IkT-01427: Inhibikase Therapeutics
Progressive Multifocal Leukoencephalopathy Companies
Over three leading companies are engaged in developing therapies for Progressive Multifocal Leukoencephalopathy (PML), with NeoImmuneTech advancing the most progressed candidates, currently in Phase I clinical trials.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Progressive Multifocal Leukoencephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Progressive Multifocal Leukoencephalopathy Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Progressive Multifocal Leukoencephalopathy Therapies and Key Companies: Progressive Multifocal Leukoencephalopathy Clinical Trials and advancements
Progressive Multifocal Leukoencephalopathy Pipeline Therapeutic Assessment
• Progressive Multifocal Leukoencephalopathy Assessment by Product Type
• Progressive Multifocal Leukoencephalopathy By Stage
• Progressive Multifocal Leukoencephalopathy Assessment by Route of Administration
• Progressive Multifocal Leukoencephalopathy Assessment by Molecule Type
Download Progressive Multifocal Leukoencephalopathy Sample report to know in detail about the Progressive Multifocal Leukoencephalopathy treatment market @ Progressive Multifocal Leukoencephalopathy Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Progressive Multifocal Leukoencephalopathy Current Treatment Patterns
4. Progressive Multifocal Leukoencephalopathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Progressive Multifocal Leukoencephalopathy Late-Stage Products (Phase-III)
7. Progressive Multifocal Leukoencephalopathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Progressive Multifocal Leukoencephalopathy Discontinued Products
13. Progressive Multifocal Leukoencephalopathy Product Profiles
14. Progressive Multifocal Leukoencephalopathy Key Companies
15. Progressive Multifocal Leukoencephalopathy Key Products
16. Dormant and Discontinued Products
17. Progressive Multifocal Leukoencephalopathy Unmet Needs
18. Progressive Multifocal Leukoencephalopathy Future Perspectives
19. Progressive Multifocal Leukoencephalopathy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Progressive Multifocal Leukoencephalopathy Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting
